Bagsværd, Denmark, Monday 1 October - Novo Nordisk today announced the establishment of a manufacturing site in Fremont, California, US to develop and produce stem cell-based therapies. The announcement follows the signing of a long-term lease on a good manufacturing practice (GMP) facility, previously operated by Asterias Biotherapeutics.
The site will support Novo Nordisk's increased commitment to develop stem-cell based therapies within type 1 diabetes and other serious chronic diseases. Once operational in 2019, the facility will fulfil the supply of stem cell-based therapies for Novo Nordisk's clinical trial programmes.
"Our ambition is to develop stem cell-based therapies for a range of serious chronic diseases where we see significant unmet medical need," said Jacob Sten Petersen, corporate vice president and head of Stem Cell Research & Development (R&D), Novo Nordisk. "The reliable, large-scale supply of therapies is a vital component in our efforts, so I am delighted that we have established this facility that further demonstrates our strong commitment to this field."
More details: https://www.novonordisk.com/media/news-details.2218411.html